Bridget Walton, MS

Linkedin Team icon

VP, Global Regulatory Affairs

Bridget Walton, MS, RAC, is an accomplished Regulatory Affairs executive with 20+ years’ experience leading global regulatory strategy in all phases of drug development and commercialization across therapeutic areas for leading pharmaceutical companies. Prior to joining MindMed, Ms. Walton held positions of increasing responsibility in Global Regulatory Affairs at Sunovion Pharmaceuticals Inc., where she led global regulatory strategy across a range of CNS disorders including schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, binge eating disorder, and Parkinson’s disease psychosis.

Ms. Walton began her career as a molecular biologist, transitioning to a career in Regulatory Affairs for Wyeth Vaccines, Johnson & Johnson Pharmaceutical Research Division, and Novartis Pharmaceuticals Corporation.

Ms. Walton holds a Bachelor of Science degree in biology / chemistry / premed from Immaculata University, a Master of Science degree in molecular biology from Villanova University, and a Master of Science degree in Regulatory Affairs and Quality Assurance from Temple University School of Pharmacy. She is currently pursuing a doctorate degree in Regulatory Science at the
University of Southern California School of Pharmacy.

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Carrie Liao, CPA

Chief Accounting Officer

Bridget Walton, MS

VP, Global Regulatory Affairs

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Peter Mack, PhD

VP, Pharmaceutical Development

Rafael Muniz, MD

VP, Global Medical Affairs

Phong Duong, PharmD

VP, Global Market Access

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor